2026 Q2 Portfolio Activity
In 2026 Q2, Aisling Capital Management LP maintained a portfolio of 14 distinct positions. The most significant new addition was VTV THERAPEUTICS INC, now representing 0.40% of the total fund value.
Position History
hover any row below to update
Loading…
Total Positions
14
Quarter
2026 Q2
Top Holding
BBIO (72.5%)
Top 10 Concentration
99.0%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-14 of 14
Aisling Capital Management LP Full Holdings List — 2026 Q2
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
BBIO
BRIDGEBIO PHARM...
|
Healthcare | 72.48% | 79.35% |
#1
Prev: #1
|
6.5 |
—
|
-500,000 | -9.8% |
P
S
|
4,589,611 | $341,834,227 | 2019 Q2 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
GLUE
MONTE ROSA THER...
|
Healthcare | 7.98% | 5.37% |
#2
1
Prev: #3
|
5.7 |
—
|
no change | no change |
P
S
|
1,555,664 | $37,647,069 | 2021 Q2 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
SNDX
SYNDAX PHARMACE...
|
Healthcare | 6.10% | 6.46% |
#3
1
Prev: #2
|
4.4 |
—
|
no change | no change |
P
S
|
1,316,806 | $28,785,379 | 2020 Q1 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
CMPS
COMPASS PATHWAY...
|
Healthcare | 4.30% | 1.66% |
#4
2
Prev: #6
|
3.2 |
—
|
no change | no change |
P
S
|
1,432,336 | $20,267,554 | 2023 Q3 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
BCAX
BICARA THERAPEU...
|
Healthcare | 3.58% | 2.38% |
#5
1
Prev: #4
|
2.9 |
—
|
no change | no change |
P
S
|
568,919 | $16,891,205 | 2024 Q3 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
BBOT
BRIDGEBIO ONCOL...
|
Healthcare | 1.64% | 1.91% |
#6
1
Prev: #5
|
1.7 |
—
|
no change | no change |
P
S
|
1,018,018 | $7,757,297 | 2025 Q3 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
SRRK
SCHOLAR ROCK HL...
|
Healthcare | 0.90% | 0.80% |
#7
Prev: #7
|
1.4 |
—
|
no change | no change |
P
S
|
77,031 | $4,236,705 | 2025 Q3 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
URGN
UROGEN PHARMA L...
|
Healthcare | 0.84% | 0.41% |
#8
2
Prev: #10
|
1.3 |
—
|
no change | no change |
P
S
|
108,000 | $3,974,400 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
BMEA
BIOMEA FUSION I...
|
Healthcare | 0.64% | 0.66% |
#9
1
Prev: #8
|
1.3 |
—
|
no change | no change |
P
S
|
2,048,757 | $3,011,673 | 2021 Q2 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
ACRS
ACLARIS THERAPE...
|
Healthcare | 0.49% | 0.34% |
#10
1
Prev: #11
|
1.2 |
—
|
no change | no change |
P
S
|
434,455 | $2,298,267 | 2018 Q4 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
EPRX
EUPRAXIA PHARMA...
|
Healthcare | 0.46% | 0.49% |
#11
2
Prev: #9
|
1.2 |
—
|
no change | no change |
P
S
|
325,000 | $2,148,250 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
VTVT
VTV THERAPEUTIC...
|
Healthcare | 0.40% | — |
#12
Prev: #—
|
3.7 |
—
|
50,000 | — |
NEW
|
50,000 | $1,882,500 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
MRKR
MARKER THERAPEU...
|
Healthcare | 0.10% | 0.09% |
#13
1
Prev: #12
|
1.0 |
—
|
no change | no change |
P
S
|
325,370 | $478,293 | 2023 Q2 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
OKUR
ONKURE THERAPEU...
|
Healthcare | 0.09% | 0.08% |
#14
1
Prev: #13
|
1.0 |
—
|
no change | no change |
P
S
|
88,607 | $404,048 | 2024 Q4 | 13F Filing | 2026-06-30 | 2026-08-13 |
Showing 1-14 of 14 holdings